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on Mondays in ICD therapies using generalized estimating equations and Student t tests. All hypothesis tests were
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occurring during this 6-h block (all p < 0.05). A signiﬁcant peak in therapies on Mondays occurred only in patients
not on beta-blocker therapy (22% of events for the week, p ¼ 0.029).Conclusions In the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) population, the distribution of life-threatening VA
failed to show a typical early morning peak or increased VA events on Mondays. A typical early morning nadir
was seen in the entire cohort. An increased rate of events on Mondays was found in the subgroup of subjects not on
beta-blocker therapy. These ﬁndings may indicate suppression of the neurohormonal triggers for VA by current heart
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13; accepted November 18, 2013.ischemic and nonischemic cardiomyopathy (9,10). These
ﬁndings suggest that some triggering mechanisms for ar-
rhythmic events are inﬂuenced by normal alterations in
biorhythms. Biorhythmic ﬂuctuations in platelet aggrega-
tion, blood pressure, heart rate, cortisol levels, catecholamine
levels, vascular tone, and ischemia are believed to underlie
the circadian patterning of myocardial infarction, ICD
shocks, and sudden cardiac death (11–13).See page 2709Clinical management of heart failure, indications for
ICD placement, and our ability to interrogate ICD elec-
trograms have evolved signiﬁcantly since earlier studies on
timing and ICD shocks were performed. Recent analyses of
temporal patterns of VA in subjects with hypertrophic
cardiomyopathy, Brugada syndrome, and early repolariza-
tion syndrome showed substantial differences in timing of
arrhythmia occurrence that may indicate differences in
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2703arrhythmia triggering mechanisms in varying pathologies
(14,15). This may have therapeutic implications, because
a vagally mediated arrhythmogenic process would be tar-
geted differently than a sympathetically driven process.
Although current conceptual models of chronobiologic
rhythms and their impact on ventricular arrhythmogenesis
have highlighted rhythmic variability in sympathetic nervous
system input as a major triggering mechanism, the data
supporting this are conﬂicting (16). Notably, adrenergic
blockade has been shown in small studies to abolish the
typical early morning VA peak (17) and in other studies to
leave typical circadian patterns unaffected (18). In an anal-
ogous area of cardiovascular disease, evidence has suggested
that hypertension chronotherapydreestablishing normal
circadian patterns in blood pressure by systematic sched-
uling of medication dosingdis associated with a signiﬁcant
reduction in cardiovascular events (19). Using the SCD-
HeFT (Sudden Cardiac Death in Heart Failure Trial) pri-
mary prevention ICD population, we sought to determine
whether the timing of ICD therapies for life-threatening
VA manifests circadian and septadian variation and
whether that pattern is importantly modiﬁed by speciﬁc
patient characteristics or heart failure therapies.
Methods
Details of SCD-HeFT have been previously reported (20).
In brief, from September 16, 1997, to July 18, 2001, 2,521
subjects were randomly assigned to receive placebo (847
subjects), amiodarone (845 subjects), or a single-chamber
ICD programmed to shock-only mode (Medtronic 7223;
829 subjects, of which 811 received an ICD). Patients
enrolled were at least 18 years of age and had New York
Heart Association (NYHA) functional class II or III, chronic
stable heart failure due to ischemic or nonischemic causes, and
a left ventricular ejection fraction (EF) of no more than 35%.
All patients signed an informed consent form, and the study
was approved by the human subjects committee of each
participating institution.
The ICD was programmed to have a single zone of
therapy, and an episode of tachycardia was deﬁned as at least
18 of 24 sequential beats at a detection rate of 187.5 beats/
min or more. Antitachycardia pacing was not speciﬁed in
the protocol but was programmed in a small number of
subjects. In contrast to prior reports (21), this analysis in-
cluded subjects who received either shocks or antitachycar-
dia pacing therapy for events classiﬁed by the electrogram
committee as an appropriate therapy for ventricular tachy-
cardia or ventricular ﬁbrillation. Subjects were followed up
every 3 months with alternating clinic visits and telephone
calls. Data from the ICD memory log were regularly
downloaded at these visits. The time and date of each
episode was collected. For subjects with arrhythmic storm,
events separated by <1 min were counted as the same event.
Data analysis. Baseline characteristics are summarized as
median (25th, 75th percentile) for continuous variables andpercent (number) for categorical
variables. The timing of episode
occurrence was examined in 2
ways: 1) on a per-episode basis,
considering each episode as a
separate observation and giving
each episode equal weight in the
analysis; and 2) on a per-patient
basis, considering each patient as
a separate observation and giving each patient equal weight
in the analysis. The latter approach circumvents the issue of
the statistical results being dominated by a few patients with
a large number of events. On the basis of time of occurrence,
each ICD therapy was assigned to one of 4 time intervals:
12 AM to 6 AM, 6 AM to 12 PM, 12 PM to 6 PM, and 6 PM to 12
AM. For each 6-h interval, the proportion of all episodes
occurring during that interval was calculated for the per-
episode approach. For the per-patient approach, we calcu-
lated a weighted frequency for each patient equal to the
proportion of episodes weighted by the inverse of the total
episodes (for example, a patient with 1 episode in a given
interval out of 4 total episodes would have a weighted fre-
quency of 0.25 for that interval).
We tested 3 hypotheses: 1) morning peak: that the
morning interval of 6 AM to 12 PM, representing 0.25 of the
24-h period, would have more than 0.25 of the episodes;
2) early morning nadir: that the early morning interval of
12 AM to 6 AM, again representing 0.25 of the 24-hour
period, would have less than 0.25 of the episodes; and
3) Monday peak: that Monday, representing 0.143 (one-
seventh) of the week, would have more than 0.143 of
the episodes. Each of these hypotheses was tested for both
the per-episode approach, using generalized estimating
equations to account for intrapatient correlation between
episodes, and the per-patient approach, using a Student
t test to compare the sample mean weighted frequency with
the stated value. However, because the results of the 2 sets of
analyses were quite similar, only the results of the per-patient
analysis are shown. All hypothesis tests were performed in
the entire cohort of patients with VA as well as subgroups
deﬁned by heart failure etiology, NYHA functional class,
age (50 years and >50 years), sex, EF (25% and >25%),
and baseline beta-blocker use. All hypothesis tests were
one sided, and p < 0.05 was considered signiﬁcant. All
analyses were conducted with SAS version 9.2 (SAS Insti-
tute, Cary, North Carolina).
Results
A total of 714 ICD therapies for life-threatening VA
occurred in 186 subjects. Baseline characteristics are pre-
sented in Table 1. Among the patients experiencing
appropriate ICD therapy for VA, the median age was 63
years and the majority were male (79%). At enrollment, 56%
of the subjects were treated with a beta-blocker and 82%
with an angiotensin-converting enzyme inhibitor. Ischemic
Table 1
Baseline Characteristics of All Subjects Who
Received ICDs and Subjects With
Spontaneous ICD Therapy for Ventricular Arrhythmia
All Patients
With ICDs
(n ¼ 811)
Patients With
Ventricular Tachycardia
and Ventricular Fibrillation
(n ¼ 186)
Age, yrs 60 (52, 69) 63 (53, 69)
Male 77 (626) 79 (147)
Ejection fraction 24 (19, 30) 20 (18, 26)
Beta-blocker 70 (565) 56 (105)
ACE inhibitor or ARB 94 (766) 94 (175)
Statin 38 (305) 34 (63)
NYHA functional class
II 68 (554) 64 (119)
III 32 (257) 36 (67)
HF etiology
Ischemic 52 (420) 51 (94)
Nonischemic 48 (391) 49 (92)
Values are median (25th, 75th percentile) or % (n).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blockade, HF ¼ heart failure;
ICD ¼ implantable cardioverter-deﬁbrillator; NYHA ¼ New York Heart Association.
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2704cardiomyopathy was present in 51%, and 64% had NYHA
functional class II chronic heart failure.
The distribution of ICD therapies over the 24-h period,
in 3-h increments, is shown in Figure 1. No clear pattern
is evident. The proportion of ICD therapies occurring in the
typical 6 AM to 12 PM interval was not signiﬁcantly >0.25,
either overall or for any subgroup (all p > 0.2) (Table 2). In
fact, for almost all subgroups, both the proportion of epi-
sodes and the mean weighted frequency during these
morning hours were <0.25.
The proportion of ICD therapies occurring in the typical
nadir of the 12 AM to 6 AM interval is shown in Table 3
and Figure 2. In the overall cohort and among patients whoFigure 1 ICD Therapies for Ventricular Arrhythmias During the 24-h P
The blue bars show the proportion of all episodes that occurred during each 3-h period, and
averaged across patients, that occurred during each 3-h period. ICD ¼ implantable cardiwere ischemic, NYHA functional class II, older, or not on a
beta-blocker, the proportion of events occurring during this
interval was signiﬁcantly less than 0.25 (all p < 0.05), with a
weighted frequency of 0.21 for all patients and a range of 0.17
to 0.19 for the 4 subgroups. The proportions are closer to
0.25 than the weighted frequencies in most subgroups,
indicating that the proportions are inﬂuenced by a subset of
patients with a larger number of episodes during the interval.
The distribution of ICD therapies over the 7-day week
for all patients is shown in Figure 3. In general, the lowest
proportion occurred on Sundays and Thursdays and highest
proportion on Tuesdays or Wednesdays. The proportion of
therapies on Mondays was not signiﬁcantly greater than
one-seventh for the entire cohort or any subgroup except
those patients not on beta-blocker therapy (Table 4).
Among those patients, the mean weighted frequency
was 0.22, indicating that nearly one-fourth of their epi-
sodes occurred on Mondays.
Discussion
Analysis of the timing of ICD therapy for life-threatening
VA in the SCD-HeFT cohort revealed a typical early
morning nadir of VA but no early morning peak or Monday
predominance. Additionally, subgroup analysis showed the
early morning nadir in patients who were ischemic, NYHA
functional class II, younger than 50 years of age, and not
on beta-blocker therapy. Conversely, we did not see a typical
morning peak of arrhythmia in any subgroup stratiﬁed by
sex, heart failure etiology, heart failure class, or beta-blocker
use. Septadian (weekly) variation was seen only in the sub-
group not on beta-blocker therapy.
Multiple prior studies have shown a circadian pattern of
ICD ﬁring, with a prominent morning peak, often a smallereriod
the green bars show the proportion of episodes, calculated for each patient and then
overter-deﬁbrillator.
Table 2
Proportion and Weighted Frequency of Events Occurring in the Morning (6 AM to 12 PM) Versus the Rest of
the 24-h Period
Number of
Patients
Number of
Episodes
Proportion (n)
Occurring During
Morning Interval
Proportion (n)
Occurring During
Other Times
Mean Weighted
Frequency During
Morning Interval
Mean Weighted
Frequency During
Other Times p Value*
All patients 186 714 0.207 (148) 0.793 (566) 0.213 0.787 0.93
HF etiology
Ischemic 94 351 0.182 (64) 0.818 (287) 0.218 0.782 0.80
Nonischemic 92 363 0.231 (84) 0.769 (279) 0.208 0.792 0.90
NYHA functional class
II 119 450 0.160 (72) 0.840 (378) 0.175 0.825 0.99
III 67 264 0.288 (76) 0.712 (188) 0.281 0.719 0.25
Ejection fraction, %
>25 47 210 0.195 (41) 0.805 (169) 0.153 0.847 0.99
25 139 504 0.212 (107) 0.788 (397) 0.234 0.766 0.71
Age, yrs
>50 155 569 0.190 (108) 0.810 (461) 0.214 0.786 0.90
50 31 145 0.276 (40) 0.724 (105) 0.212 0.788 0.77
On beta-blocker at baseline
Yes 105 459 0.198 (91) 0.802 (368) 0.175 0.825 0.99
No 81 255 0.224 (57) 0.776 (198) 0.263 0.737 0.38
Sex
Female 39 148 0.216 (32) 0.784 (116) 0.223 0.777 0.67
Male 147 566 0.205 (116) 0.795 (450) 0.211 0.789 0.92
*p values are from tests of the hypothesis that the mean weighted frequency will be >0.25, that is, that the proportion of patients’ events occurring from 6 AM to 12 PM will be greater than one-fourth.
Abbreviations as in Table 1.
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2705secondary late afternoon peak, and an early morning nadir
(4,5,18,22,23). Toﬂer et al. (8), in the ﬁrst large study of the
timing of ICD shocks, analyzed data from 483 patients
with a Ventak PRx ICD (Guidant, St. Paul, Minnesota)
implanted between 1990 and 1993. A circadian pattern withTable 3
Proportion and Weighted Frequency of Events Occurring in t
the 24-h Period
Proportion (n)
Occurring During
Night Interval
Proportion
Occurring Du
Other Time
All patients 0.241 (172) 0.759 (54
HF etiology
Ischemic 0.236 (83) 0.764 (26
Nonischemic 0.245 (89) 0.755 (27
NYHA functional class
II 0.233 (105) 0.767 (34
III 0.254 (67) 0.746 (19
Ejection fraction, %
>25 0.238 (50) 0.762 (16
25 0.242 (122) 0.758 (38
Age, yrs
>50 0.241 (137) 0.759 (43
50 0.241 (35) 0.759 (11
On beta-blocker therapy at baseline
Yes 0.251 (115) 0.749 (34
No 0.224 (57) 0.776 (19
Sex
Female 0.270 (40) 0.730 (10
Male 0.233 (132) 0.767 (43
*p values are from tests of the hypothesis that the mean weighted frequency will be <0.25, that is, tha
Abbreviations as in Table 1.a peak between 9 AM and 12 PM and a nadir between 3 AM
and 6 AM was seen in both groups (p < 0.001). The results
did not differ within subgroups of age, sex, EF, NYHA
functional class, or heart failure etiology. The group with
EF <20% or NYHA functional class III chronic hearthe Early Morning (12 AM to 6 AM) Versus the Rest of
(n)
ring
s
Mean Weighted
Frequency During
Night Interval
Mean Weighted
Frequency During
Other Times p Value*
2) 0.207 0.793 0.048
8) 0.168 0.832 0.0092
4) 0.247 0.753 0.47
5) 0.188 0.812 0.023
7) 0.242 0.758 0.43
0) 0.184 0.816 0.081
2) 0.215 0.785 0.13
2) 0.191 0.809 0.016
0) 0.290 0.710 0.72
4) 0.226 0.774 0.26
8) 0.182 0.818 0.032
8) 0.209 0.791 0.25
4) 0.207 0.793 0.064
t the proportion of patients’ events occurring from 12 AM to 6 AM will be less than one-fourth.
Figure 2 Mean Weighted Frequency of ICD Therapies During the 12 AM to 6 AM Interval, Overall and by Subgroup
The bars show the mean proportion of each patient’s episodes that occurred between 12 AM and 6 AM. The asterisks denote subgroups in which this mean proportion is less than
0.25, the proportion under the null hypothesis. HF ¼ heart failure; NYHA ¼ New York Heart Association; other abbreviation as in Figure 1.
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2706failure was notable for an attenuated nighttime decrease in
arrhythmia frequency and a blunted morning peak.
Mallavarapu et al. (24) analyzed the timing of VA epi-
sodes in 390 patients with healed myocardial infarction
and assessed whether the circadian pattern was inﬂuenced
by sex, age, left ventricular function, or ventricular tachy-
cardia cycle length <300 ms or >300 ms. A total of
15,731 device detections occurred, of which 2,692 elec-
trograms were available and consistent with VA (2,488
episodes treated, 208 episodes with therapy aborted).
Circadian variation in the occurrence of VA was evident,
with the highest rate between 10 AM and 11 AM and theFigure 3 ICD Therapies for Ventricular Arrhythmias During the 7-Day
The blue bars show the proportion of all episodes that occurred during each day, and the
averaged across patients, that occurred during each day. Abbreviation as in Figure 1.lowest rate between 2 AM and 3 AM. This pattern persisted
regardless of subgroup.
In 2 analyses, Peters et al. (7,25) investigated the septadian
distribution of ICD shocks and the interaction of septadian
and circadian rhythms in 683 patients with a Ventak PRx
ICD. The circadian pattern of ICD shock for episodes with
a cycle length <280 ms showed a broad peak between 9 AM
and 6 PM and a long nadir between 9 PM and 6 AM. The daily
event timing distribution was strikingly similar for each day
of the week, despite twice as many discharges on Mondays as
compared with Saturdays. The circadian variation was in-
dependent of age, sex, EF, NYHA functional class,Week
green bars show the proportion of episodes, calculated for each patient and then
Table 4 Proportion and Weighted Frequency of Events Occurring on Mondays Versus the Rest of the Week
Proportion (n)
Occurring on
Mondays
Proportion (n)
Occurring on
Other Days
Mean Weighted
Frequency on
Mondays
Mean Weighted
Frequency on
Other Days p Value*
All patients 0.148 (106) 0.852 (608) 0.161 0.839 0.22
HF etiology
Ischemic 0.128 (45) 0.872 (306) 0.153 0.847 0.38
Nonischemic 0.168 (61) 0.832 (302) 0.168 0.832 0.21
NYHA functional class
II 0.149 (67) 0.851 (383) 0.164 0.836 0.24
III 0.148 (39) 0.852 (225) 0.155 0.845 0.37
Ejection fraction, %
>25 0.171 (36) 0.829 (174) 0.151 0.849 0.44
25 0.139 (70) 0.861 (434) 0.164 0.836 0.21
Age, yrs
>50 0.155 (88) 0.845 (481) 0.160 0.840 0.26
50 0.124 (18) 0.876 (127) 0.166 0.834 0.33
On beta-blocker therapy at baseline
Yes 0.150 (69) 0.850 (390) 0.115 0.885 0.85
No 0.145 (37) 0.855 (218) 0.220 0.780 0.029
Sex
Female 0.209 (31) 0.791 (117) 0.153 0.847 0.43
Male 0.133 (75) 0.867 (491) 0.163 0.837 0.22
*p values are from tests of the hypothesis that the mean weighted frequency will be >0.143, that is, that the proportion of patients’ events occurring on Mondays will be greater than one-seventh.
Abbreviations as in Table 1.
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2707etiology of heart failure, and use of antiarrhythmic drugs but
was not seen in patients on beta-blocker therapy.
Prior large and small studies predominantly included
subjects with coronary artery disease. Englund et al. (26)
reported an analysis of a more mixed population of
ischemic and nonischemic chronic heart failure. Between
1993 and 1994, 820 patients received an ICD, and 310
had an episode of VA. Both groups had similar circadian
patterns of events, with a pronounced morning and a less
pronounced afternoon peak. Analogous data showing
similar circadian distributions of ventricular tachycardia
episodes in ischemic and nonischemic cardiomyopathy
were also reported by Grimm et al. (10).
Several prior studies have investigated the relationship
between NYHA functional class or EF and circadian pattern
of VA (4,5,8,22,24). Three studies did not show a difference
in the timing of VA in subgroup analysis that included EF
or NYHA functional class (5,22,24), whereas Behrens et al.
(4) found no typical circadian pattern in class III subjects
and Toﬂer et al. (8) described a blunted morning peak and
attenuation of the nighttime nadir in class IV subjects and
those with EF <20%. In our study, an early nadir was found
in the overall cohort but on subgroup analysis only in sub-
jects with class II heart failure, ischemic cardiomyopathy,
age younger than 50 years, and beta-blocker therapy. It is
curious that both the older and sicker patients had an
attenuated circadian pattern, as well as the nonischemic
patients and those treated with adrenergic blockade. A
critical difference in our population compared with prior
studies is the mean EF of 20%; the mean EF in all prior
studies but one was >30%. This difference may play afundamental role in the dissimilarity of speciﬁc triggers for
episodes of VA or may reﬂect other pathways of autonomic
dysregulation, such as severe heart failure.
Our study population differs from prior reports in ways
important to the underlying pathophysiological processes
involved in arrhythmia generation. SCD-HeFT was a pro-
spective randomized clinical trial designed to evaluate ICD
therapy in the primary prevention of sudden cardiac death.
Prior studies of biorhythmic effects on VA occurrence have
examined predominantly secondary prevention patients,
with mostly ischemic heart disease and higher EFs. In our
study, stored electrograms for each episode were available
and adjudicated by the SCD-HeFT Electrogram Commit-
tee, data that were similarly available in only one prior study.
Because the majority of the foundational research in the area
of circadian variation in ICD shocks was performed more
than a decade ago, major changes in heart failure therapy
have occurred. More than 90% of the SCD-HeFT ICD
subjects were treated with angiotensin-converting enzyme
inhibitors or angiotensin receptor blockade, the majority
was treated with a beta-blocker, and 38% were treated with
a statin. Given the myriad effects of these agents, which
include anti-ischemic, anti-inﬂammatory, and vaso-
dilatory properties, any of these agents, or a synergistic
combination, may account for the attenuation in usual
circadian patterns seen in this study.
The inﬂuence of circadian rhythms on the occurrence
of cardiovascular events is often explained by a morning
surge of sympathetic nervous system activity resulting in
physiological changes that produce myocardial ischemia
(11,13). This has also led to the hypothesis that a subset of
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2708episodes of VAs and sudden cardiac death corresponding
to these circadian surges may be aborted by treating pa-
tients with beta-blockers. Notably, the signiﬁcant result
in the full cohort is driven by the pattern in the patients
with ischemic cardiomyopathy. Our ﬁndings support the
ischemia hypothesis in that we found an attenuation of
circadian and septadian rhythms in subjects on beta-
blocker therapy; in the SCD-HeFT ICD arm, 57% of
the subjects who received ICD shocks for VAs and 70% of
all patients who received an ICD were treated with beta-
blockade. It is tempting to speculate that the increased
rate of neurohormonal suppression of adrenergic triggers
of VAs modulated the previously observed circadian and
septadian patterns. Additional evidence for this is that the
SCD-HeFT subgroup of subjects not on beta-blocker
therapy showed more traditional variation in timing of
arrhythmia, with the early morning nadir, and increased
prevalence on Mondays.
Study limitations. Limitations of this study include the
post-hoc nature of the analysis. Additionally important to note
is the lack of data regarding work schedules or sleep-wake
schedules, timing of medication ingestion, or consumption
of alcohol, caffeine, and other sympathomimetic substances.
Conclusions
In the SCD-HeFT primary prevention population, the time
distribution of ICD therapies for life-threatening VA shows
an early morning nadir in the occurrence of VA but no
overall typical morning peak or increase in events on
Mondays. Subgroup analysis showed a more prominent
typical early morning nadir in ischemic patients, those with
NYHA functional class II heart failure, and younger sub-
jects. Subjects not on beta-blocker therapy also had an
increased event rate on Mondays. These ﬁndings may
indicate suppression of neurohormonal triggers with current
heart failure therapy.
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